Invests in
Sectors:
Min Investment:
$100,000.00Max Investment:
$1,000,000.00Target Investment:
$300,000.00
Skills
Education
Lists including Milad
Investments
Future Fields
Total Funding: $13M
Eigen Therapeutics
Total Funding: $7M
Seqera
Total Funding: $28M
Wayfinder Biosciences
Total Funding: $4.3M
Arpeggio Bio
Total Funding: $20M
Notable Labs
Total Funding: $55M
Character Biosciences
Total Funding: $24M
CytoTronics
Total Funding: $9M
DrugBank
Total Funding: $12M
Colossal Biosciences
Total Funding: $390M
Work Experience
2024
Co-Founder
2024
We work closely with hospitals and organ procurement organizations to enable organ donation after patients pass away from incurable diseases like lung cancer that traditionally prevent donation for clinical transplantation. We then bring those organs back to life on organ perfusion technology to run transformative research studies aimed at accelerating the development of breakthrough biomedical innovations without putting patient’s lives at risk.
Co-Founder & Co-Host Code to Cure Series
2024
2020
First investor and Board Member
2020
First investor and board member. Seqera is building the modern biotech stack by making scientific data analysis accessible at any scale. Seqera is the best solution for running robust, high-throughput computing at scale. From your first pipeline to running 10,000+ concurrent CPUs or workflows with >1,000,000 tasks, Seqera's architecture will grow with you - ensuring that computational bottlenecks never hinder scientific endeavors.
Visiting Scientist & Senior Advisor
2024
To become a leading independent research institute in the discovery and development of innovative solutions to improve human health. https://www.indianabiosciences.org/
Senior Advisor
2024
16 Tech is a 50-acre innovation district in downtown Indianapolis dedicated to world-changing innovation and economic opportunity.
2024
Strategic Expert in Residence
2024
Through Digitalis Commons, I am a Strategic Expert in Residence in support of the Advanced Research Projects Agency for Health (ARPA-H), where I support the US government and ARPA-H mission of enabling transformative biomedical and health breakthroughs to provide health solutions for all through non-dilutive investments. https://arpa-h.gov/
2024
Member
2024
Established in 2009, C100 is a non-profit association with a mission to showcase exceptional leadership, harness extraordinary international talent, and fuel the pursuit of daring entrepreneurial ambitions in Canada.
2019
Mentor - Recipient of Mentor of the Year Award
2019
Recipient of Mentor of the Year Award. Creative Destruction Lab (CDL) is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies. Its nine-month program allows founders to learn from experienced entrepreneurs, increasing their likelihood of success. The program has expanded to 12 sites across six countries. Participating ventures have created $28 billion (CAD) in equity value.
2023
Board Member
2023
Talus Bio is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology.
2018 - 2024
Head of Life Sciences & Deep Tech
2018 - 2024
After nearly six incredible years, I have officially left BoxOne Ventures, filled with gratitude and excitement. My journey has been transformative, and I am immensely proud of what we have achieved together. In 2018, I met Josh at Creative Destruction Lab. We connected over our mutual passion for pushing the boundaries of bioengineering and computational advancement. We immediately began finding ways to work together and make investments, often as the first check into startups run by world-class founders. Fast forward nearly six years, we've built a firm recognized as one of the most active early-stage investors, with a portfolio exceeding 100 companies and multiple successful exits. Our brand stands as a testament to our founders and community partners who collaborate with us to make this possible.